Forbes: Critical Reports Mount On Hepatitis C Pill Costs
The staggering costs of hepatitis C pills are the subject of two new medical journal reports pointing out that employers, insurers and the U.S. government will have difficulty paying for these pricey pills for years to come.
The new issue of the Annals of Internal Medicine, the journal published by the American College of Physicians, says the new costs of hepatitis C treatments are “reaching an average of $27 billion a year, which is equivalent to 10 percent of U.S. prescription spending,” researchers at M.D. Anderson Cancer Center wrote in the March 17 issue. And in the journal Clinical Infectious Diseases, authors from the University of Chicago say “pent up demand for treatment may create challenges for financing.”